BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
America's Confided in Cooler in 2024 - 2Doctors seek to understand why quitting antidepressants causes withdrawal for some
- 3Vote in favor of Your Number one kind of pie
- 4Israel's haredi draft crisis: Court ruling and political stalemate reach breaking point
- 5Iran's stolen futures: The arrested Iranians at risk of execution by the regime
- Israel, Gulf states report fresh missile and drone attacks
- Overseeing Individual budgets Successfully
- 10 Distinct Kinds of Chinese Neighborhood Specialty Hot Pot
- 'Stranger Things' series finale trailer shows Hawkins gang gearing up for last battle with Vecna
- France's Senate backs ban on social media platforms for under-15s
- As juries turn against social media for harming kids, Big Tech's invincibility starts to show cracks
- The Drone Video of the Year is stunning – you've not seen Namibia like this
- Moon-bound Artemis II astronauts enjoy a relaxed day in space
- Vote In favor of Your Favored Occasion Arranging Administration
